Sedative-hypnotic use disorders

Mechanism of Action - GABA's Gatekeepers

• Primary Action: All sedative-hypnotics potentiate the inhibitory neurotransmitter GABA at the $GABA_A$ receptor, leading to ↑ influx of chloride ions ($Cl^⁻$) and neuronal hyperpolarization.

• Benzodiazepines (BDZs): Increase the frequency of channel opening.

  • 📌 Mnemonic: 'Ben-zo-FRE-nzo' for ↑ FREquency.

• Barbiturates (Barbs): Increase the duration of channel opening.

• Z-drugs (Zolpidem, Zaleplon): Act on a specific subunit of the BDZ receptor.

⭐ Barbiturates are more dangerous in overdose because at high doses, they can directly open GABA-A channels without GABA. Benzodiazepines require GABA to be present, giving them a better safety profile.

Intoxication & Overdose - The Big Slump

• Clinical Picture: Mimics alcohol intoxication, causing widespread CNS depression.

  • Early signs: Drowsiness, euphoria, poor coordination, and disinhibition.
  • Progressive symptoms: Ataxia, slurred speech, poor judgment, and anterograde amnesia.

• Severe Overdose: A medical emergency due to profound vital sign suppression.

  • Respiratory depression (rate < 12/min) is the primary cause of mortality.
  • Hypotension and bradycardia may lead to cardiovascular collapse.
  • Stupor progressing to deep coma.

• Overdose Management:

⭐ High-Yield: Flumazenil (a competitive benzodiazepine antagonist) can precipitate life-threatening withdrawal seizures in chronic benzodiazepine users or those who co-ingested a pro-convulsant (e.g., TCA). Its use is highly restricted.

Withdrawal Syndrome - The Rebound Terror

Abrupt cessation after prolonged use triggers a severe, life-threatening rebound of CNS hyperactivity, clinically similar to delirium tremens from alcohol withdrawal.

• Core Features (Progressive):

  • Initial: Anxiety, insomnia, restlessness, autonomic hyperactivity (tremor, diaphoresis, palpitations, ↑ BP, ↑ HR).
  • Severe: Perceptual disturbances (visual, tactile, or auditory hallucinations), paranoid psychosis.
  • Life-Threatening: Generalized tonic-clonic seizures, hyperthermia, and cardiovascular collapse.

• Withdrawal Timeline (by Half-Life):

⭐ Similar to alcohol, sedative-hypnotic withdrawal can be fatal. It must be managed medically, typically with a symptom-triggered or fixed-schedule taper using a long-acting benzodiazepine (e.g., chlordiazepoxide, diazepam).

Treatment & Management - The Slow Descent

⭐ The core principle is substituting the patient's short-acting sedative with an equivalent dose of a long-acting one (e.g., chlordiazepoxide, diazepam), then slowly tapering the long-acting agent.

• Gradual Taper: The cornerstone of management to prevent severe withdrawal. Taper rate is typically a 10-25% reduction every 1-2 weeks.
• Psychological Support: Cognitive Behavioral Therapy (CBT) is crucial for addressing underlying anxiety and developing coping strategies.

High‑Yield Points - ⚡ Biggest Takeaways

• Sedative-hypnotics, like benzodiazepines and barbiturates, potentiate GABA-A receptor activity.
• Intoxication causes CNS depression, with slurred speech, ataxia, and potentially fatal respiratory depression.
• Withdrawal is life-threatening, mirroring alcohol withdrawal with tremors, anxiety, psychosis, and seizures.
• Flumazenil reverses benzodiazepine overdose but risks inducing seizures in dependent users.
• Barbiturate overdose has no antidote; management is purely supportive.
• High cross-tolerance exists between all sedative-hypnotics and alcohol.